Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innate Pharma
Biotech
Innate's NK cell engager latest victim of pipeline refocus
Innate has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
James Waldron
Mar 26, 2026 5:20am
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
Sep 19, 2025 8:30am
Innate loses 30% of workforce in focus on 'highest-value assets'
Sep 17, 2025 5:16am
Innate says lymphoma data shows anti-KIR3DL2 antibody’s promise
May 23, 2025 5:13am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
Innate antibody pits NK cells against lymphoma in animal models
Nov 15, 2024 2:00pm
